S & T Corporation Limited (BOM:514197)
India flag India · Delayed Price · Currency is INR
5.89
+0.01 (0.17%)
At close: Aug 12, 2025

SpringWorks Therapeutics Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Operating Revenue
1.751.730.454.919.889.35
Other Revenue
3.152.82--0.010.03
4.94.550.454.919.899.38
Revenue Growth (YoY)
113.78%921.08%-90.92%-50.35%5.47%-16.27%
Cost of Revenue
0.640.280.020.03--
Gross Profit
4.264.270.424.899.899.38
Selling, General & Admin
3.543.691.511.020.90.79
Other Operating Expenses
--0.292.41.971.93
Operating Expenses
3.723.871.973.63.092.99
Operating Income
0.550.41-1.551.296.86.39
Interest Expense
-0-0----
Interest & Investment Income
--0.01---
EBT Excluding Unusual Items
0.540.4-1.531.296.86.39
Other Unusual Items
------3.31
Pretax Income
0.540.4-1.531.296.83.08
Net Income
0.540.4-1.531.296.83.08
Net Income to Common
0.540.4-1.531.296.83.08
Net Income Growth
----81.03%120.99%3634.73%
Shares Outstanding (Basic)
384032323232
Shares Outstanding (Diluted)
384032323232
Shares Change (YoY)
16.77%26.29%----
EPS (Basic)
0.010.01-0.050.040.210.10
EPS (Diluted)
0.010.01-0.050.040.210.10
EPS Growth
----81.28%122.56%4702.40%
Free Cash Flow
-13.64-23-30.81193.46
Free Cash Flow Per Share
-0.34-0.72-0.973.740.11
Gross Margin
86.98%93.83%94.62%99.49%100.00%100.00%
Operating Margin
11.16%8.89%-346.41%26.27%68.75%68.10%
Profit Margin
11.10%8.83%-343.27%26.27%68.75%32.81%
Free Cash Flow Margin
-299.47%-5157.40%-627.06%1203.00%36.87%
EBITDA
0.720.58-1.371.477.026.66
EBITDA Margin
14.75%12.76%-29.83%70.93%70.98%
D&A For EBITDA
0.180.180.180.180.220.27
EBIT
0.550.41-1.551.296.86.39
EBIT Margin
11.16%8.89%-26.27%68.75%68.10%
Revenue as Reported
4.94.552.115.439.899.38
Advertising Expenses
--0.120.040.01-
Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.